Printer Friendly

IMRE CORPORATION RESUMES SHIPMENT OF PRODUCT

 SEATTLE, Dec. 28 /PRNewswire/ -- IMRE Corporation (NASDAQ: IMRE) today announced that the Food and Drug Administration (FDA) has granted the company permission to make its product available to patients urgently needing its PROSORBA(R) column treatment prior to formal approval by the FDA of the company's new manufacturing facility.
 The PROSORBA column will be shipped immediately to treat patients with immune thrombocytopenic purpura (ITP) who have failed other therapies and are predisposed to bleeding episodes due to low blood- clotting elements. The company is also working closely with the FDA to seek approval of its new manufacturing facility in the near future.
 "The company appreciates the assistance that the FDA has provided to address a potential public health issue which could have resulted from shipment delays of the PROSORBA column," stated Dr. Frank R. Jones, chairman and chief executive officer of IMRE.
 IMRE Corporation is a medical products company that is the leader in the field of immunoadsorption treatments. The company's first product, the PROSORBA column, has been approved by the Food and Drug Administration for the treatment of immune thrombocytopenic purpura, an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases, and certain cancers.
 -0- 12/28/92
 /CONTACT: Lois Yoshida of IMRE, 206-298-9400, or Ron Stabiner of the Wall Street Group, 212-888-4848, for IMRE/
 (IMRE)


CO: IMRE Corporation ST: Washington IN: MTC SU:

PS -- NY004 -- 9962 12/28/92 08:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 28, 1992
Words:241
Previous Article:'MARKETPLACE' PRESENTS SPECIAL NEW YEAR'S DAY PROGRAM WITH EXPERTS OFFERING 1993 FORECASTS
Next Article:FORD NAMES NEW MANAGER OF ATLANTA ASSEMBLY PLANT
Topics:


Related Articles
IMRE CORPORATION ANNOUNCES THIRD QUARTER RESULTS
FDA APPROVES IMRE'S NEW MANUFACTURING FACILITY
IMRE CORPORATION ANNOUNCES YEAR-END RESULTS
IMRE: MORE TTP/HUS DATA TO BE REQUIRED
IMRE ANNOUNCES PATENTS THAT EXPAND BUSINESS OPPORTUNITIES
IMRE CORPORATION ANNOUNCES FIRST QUARTER RESULTS
IMRE AND BAXTER SIGN DISTRIBUTION AGREEMENT
IMRE CORPORATION ANNOUNCES YEAR-END RESULTS
IMRE CORPORATION ANNOUNCES SECOND QUARTER RESULTS
IMRE CORPORATION ANNOUNCES YEAR END RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters